About Us

Press Releases

Press Releases

Date	Title
May 24, 2018	Prothena Announces Reorganization to Focus Resources on Advancing Neuroscience Pipeline DUBLIN, Ireland, May 24, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage biotechnology company focused on the discovery and development of novel therapies in the neuroscience category, today announced that the Company has initiated a reorganization to align its
May 08, 2018	Prothena Reports First Quarter 2018 Financial Results and Provides R&D Update Net cash used in operating and investing activities was $31.8 million in the first quarter; quarter-end cash and restricted cash position of $433.1 million supports advancement through key milestones of R&D pipeline Entered into global neuroscience research & development collaboration with Celgene
May 01, 2018	Prothena to Report First Quarter 2018 Financial Results on May 8 DUBLIN, Ireland, May 01, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical-stage biotechnology company focused on the discovery and development of novel therapies in the neuroscience and orphan categories, will announce financial results for the first quarter of 2018 on
Apr 23, 2018	Prothena Discontinues Development of NEOD001 for AL Amyloidosis Phase 2b PRONTO study did not meet its primary or secondary endpoints Phase 3 VITAL Amyloidosis Study being discontinued based on futility analysis Investor conference call and webcast today at 8:30 AM ET DUBLIN, Ireland, April 23, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a
Mar 20, 2018	Prothena Announces Global Neuroscience Research & Development Collaboration with Celgene for Novel Therapies for Patients with Neurodegenerative Diseases Prothena to receive a $100 million upfront payment and a $50 million equity investment by Celgene, with potential license payments and regulatory and commercial milestones, plus additional royalties on net sales from licensed programs Collaboration focuses on preclinical programs targeting proteins
Mar 12, 2018	Prothena to Present a Broad Range of Scientific and Health Outcomes Data at the 16th International Symposium on Amyloidosis DUBLIN, Ireland, March 12, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel therapies in the neuroscience and orphan categories, today announced that it will present new
Mar 07, 2018	Prothena to Participate in the Barclays Global Healthcare Conference DUBLIN, Ireland, March 07, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel therapies in the neuroscience and orphan categories, today announced that members of its
Feb 14, 2018	Prothena Reports Fourth Quarter and Full Year 2017 Financial Results, and Provides Financial Guidance and R&D Update Net cash used in operating and investing activities was $39.9 million in the fourth quarter and $134.7 million for the full year 2017; quarter-end cash and restricted cash position of $421.7 million supports advancement through key milestones of R&D pipeline Completed enrollment in the Phase 2b
Feb 07, 2018	Prothena to Participate in the Leerink Partners 7th Annual Global Healthcare Conference DUBLIN, Ireland, Feb. 07, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel therapies in the neuroscience and orphan categories, today announced that members of its senior
Feb 02, 2018	Prothena Announces Departure of Chief Medical Officer DUBLIN, Ireland, Feb. 02, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, announced today that Sarah Noonberg, MD, PhD, has decided to resign